Loading...
Abilify, Abilify Maintena
Antipsychotic • Second-generation (atypical) antipsychotic
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors
Drug Class
Antipsychotic
Subclass
Second-generation (atypical) antipsychotic
Half-life
75-94 hours
Time for plasma concentration to decrease by 50%
Protein Binding
>99%
Fraction bound to plasma proteins
Therapeutic Index
Wide
Margin between therapeutic and toxic doses